Incyte upgraded to Buy on strong pipeline progress and promising Phase 3 data for Monjuvi.

Incyte has been upgraded to a Buy rating due to encouraging progress in its drug pipeline and improved earnings per share estimates. Promising Phase 3 trial results for Monjuvi in first-line diffuse large B-cell lymphoma (DLBCL) suggest potential market share gains despite competition. The acquisition of Vega Therapeutics adds a new hematology drug, VGA039, to Incyte's portfolio. Additionally, a partnership in AI drug discovery and growth beyond its Jakafi product support confidence in the company's long-term prospects.